Navigating the clinical benefits, risks, and emerging controversies with glucagon-like peptide-1 receptor agonists.

Abstract

Purpose of review: The purpose of this review is to provide an overview of the current clinical implications, benefits, and controversies surrounding the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This review discusses the potential risks associated with GLP-1 RA therapy, such as pulmonary aspirations, tachyphylaxis, and issues with drug efficacy over time.Furthermore, it examines the increasing ethical and medical concerns related to their off-label use, safety, and accessibility.

Recent findings: Recent studies highlight significant discrepancies in the recommendations provided by different medical societies on the perioperative management of GLP-1 RAs. In addition, insurance barriers exacerbate access issues, with substantial disparities in coverage for weight loss versus diabetes management. The rise of counterfeit GLP-1 RAs, unintentional overdoses, and the growing concern about long-term health impacts are also prominent challenges in the current landscape.

Summary: Despite increasing usage and the potential benefits of GLP-1 RAs, a lack of consensus on optimal perioperative management and long-term use, coupled with financial and regulatory barriers, creates significant challenges. Medical societies differ on key aspects such as fasting requirements and the risk of aspiration, and concerns about the safety of compounded and counterfeit products remain.